JOIN THE BNMS             


Twitter @BNMSnews

Use of somatostatin analogue-based PRRNT

The International Atomic Energy Agency (IAEA), in cooperation with the EANM Therapy,
Oncology and Dosimetry Committees and with the Society of Nuclear Medicine and Molecular Imaging worked together to create this guidance document on the use of somatostatin analogue-based PRRNT.
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.